In vitro activity of bedaquiline against slow-growing nontuberculous mycobacteria

References

1. Tortoli E. Microbiological features and clinical relevance of new species of the genus Mycobacterium . Clin Microbiol Rev 2014; 27:727–752 [View Article]
   [Google Scholar]
2. Martiniano SL, Nick JA, Daley CL. Nontuberculous mycobacterial infections in cystic fibrosis. Clin Chest Med 2016; 37:83–96 [View Article]
   [Google Scholar]
3. Sommerstein R, Schreiber PW, Diekema DJ, Edmond MB, Hasse B et al. Mycobacterium chimaera outbreak associated with heater-cooler devices: piecing the puzzle together. Infect Control Hosp Epidemiol 2017; 38:103–108 [View Article]
   [Google Scholar]
4. Esteban J, García-Pedrazuela M, Muñoz-Egea MC, Alcaide F et al. Current treatment of nontuberculous mycobacteriosis: an update. Expert Opin Pharmacother 2012; 13:967–986 [View Article]
   [Google Scholar]
5. Philley JV, DeGroote MA, Honda JR, Chan MM, Kasperbauer S et al. Treatment of non-tuberculous mycobacterial lung disease. Curr Treat Options Infect Dis 2016; 8:275–296 [View Article]
   [Google Scholar]
6. Andries K, Verhasselt P, Guillemont J, Göhlmann HWH, Neefs J-M et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis . Science 2005; 307:223–227 [View Article]
   [Google Scholar]
7. Palomino JC, Martin A. TMC207 becomes bedaquiline, a new anti-TB drug. Future Microbiol 2013; 8:1071–1080 [View Article]
   [Google Scholar]
8. Huitric E, Verhasselt P, Andries K, Hoffner SE et al. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2007; 51:4202–4204 [View Article]
   [Google Scholar]
9. Alexander DC, Vasireddy R, Vasireddy S, Philley JV, Brown-Elliott BA et al. Emergence of mmpT5 variants during bedaquiline treatment of Mycobacterium intracellulare lung disease. J Clin Microbiol 2017; 55:574–584 [View Article]
   [Google Scholar]
10. Aguilar-Ayala DA, Cnockaert M, André E, Andries K, Gonzalez-Y-Merchand JA et al. In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria. J Med Microbiol 2017; 66:1140–1143 [View Article]
    [Google Scholar]
11. Palomino JC, Martin A, Camacho M, Guerra H, Swings J et al. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis . Antimicrob Agents Chemother 2002; 46:2720–2722 [View Article]
    [Google Scholar]
12. Martin A, Camacho M, Portaels F, Palomino JC et al. Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method. Antimicrob Agents Chemother 2003; 47:3616–3619 [View Article]
    [Google Scholar]
13. Dupont C, Viljoen A, Thomas S, Roquet-Banères F, Herrmann JL et al. Bedaquiline inhibits the ATP synthase in Mycobacterium abscessus and is effective in infected zebrafish. Antimicrob Agents Chemother 2017; 61:e01225–17 [View Article]
    [Google Scholar]
14. Brown-Elliott BA, Philley JV, Griffith DE, Thakkar F, Wallace RJ et al. In vitro susceptibility testing of bedaquiline against Mycobacterium avium complex. Antimicrob Agents Chemother 2017; 61:e01798–16 [View Article]
    [Google Scholar]
15. Pang Y, Zheng H, Tan Y, Song Y, Zhao Y et al. In vitro activity of bedaquiline against nontuberculous mycobacteria in China. Antimicrob Agents Chemother 2017; 61:e02627–16 [View Article]
    [Google Scholar]
16. Lounis N, Gevers T, Van den Berg J, Vranckx L, Andries K et al. ATP synthase inhibition of Mycobacterium avium is not bactericidal. Antimicrob Agents Chemother 2009; 53:4927–4929 [View Article]
    [Google Scholar]
17. Soni I, De Groote MA, Dasgupta A, Chopra S et al. Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria. J Med Microbiol 2016; 65:1–8 [View Article]
    [Google Scholar]
18. Ruth MM, Sangen JJN, Remmers K et al. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria. J Antimicrob Chemother 2019
    [Google Scholar]